UnitedHealth Group Incorporated UNH reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.11, which beat the Zacks Consensus Estimate of $2.09. However, the bottom line declined 69% ...
Vertex Pharmaceuticals is set to build upon its success cystic fibrosis (CF) and its potential blockbuster Casgevy through its non-opioid pain and renal therapy pipelines, says CEO Reshma Kewalramani.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results